Key result
Troponin testing for acute coronary syndromes has several shortfalls, including misleading results in heart failure, lack of standardization, and false positives from interfering antibodies.
Why the study?
Are there limitations to using troponin levels to guide glycoprotein IIb/IIIa inhibitor therapy in acute coronary syndromes as recommended by NICE guidelines?
Are there limitations to using troponin levels to guide glycoprotein IIb/IIIa inhibitor therapy in acute coronary syndromes as recommended by NICE guidelines?
Answers are grounded in this paper and cite their sources.
Highlights the limitations and potential pitfalls of relying solely on troponin levels to guide glycoprotein IIb/IIIa inhibitor therapy in acute coronary syndromes as recommended by NICE guidelines.
The guidelines on the use of glycoprotein IIb/IIIa inhibitors for acute coronary syndromes issued by the National Institute for Clinical Excellence (NICE) recommend that blood troponin is used to identify patients who might benefit from therapy. There are, however, a number of circumstances in which troponin results may be misleading. Firstly, the trials which comprise the evidence base for the therapeutic effect were only based on patients with documented coronary artery disease. Secondly, troponin is elevated in patients with heart failure and concentrations fall with appropriate treatment. Thirdly, there is no internationally accepted standard for troponin, and there are therefore important differences at the 'cut-off' values between the methods of different manufacturers. Fourthly, immunoassays suffer from interfering antibodies and at least 17 case reports have been published outlining false positive tests. It is important that the shortfalls of troponin tests in the diagnosis of acute coronary syndromes are widely recognized.
No takes yet. Share an insight, caveat, or question.
Thomson et al. (2002) conducted an editorial in acute coronary syndromes. Troponin testing was evaluated. Troponin testing for acute coronary syndromes has several shortfalls, including misleading results in heart failure, lack of standardization, and false positives from interfering antibodies.
Synapse has enriched 10 related papers. Consider them for comparative context: